Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alaric DeArment

Reporter

Alaric has been covering the biopharma industry and health care for more than 14 years. His areas of focus include clinical trials, drug development in hematology-oncology, cell and gene therapy and the industry's growing use of artificial intelligence and machine learning. He holds a bachelor's degree in journalism from Ball State University and previously lived in China for three years.

Latest From Alaric DeArment

Esperion Hopes CVOT Will Help Drive Nexletol/Nexlizet’s Market Uptake

The drugs have been slow to catch on since approval more than two years ago, but results showing reduction in cardiovascular events could help it gain traction.

Clinical Trials Cardiovascular

Summit Bets On Akeso IO Bispecific Despite China Firms’ Issues With US FDA

Deal Snapshot: Akeso has already sought to secure FDA approval for its PD-1 inhibitor, but the agency has shown reluctance to approve drugs based on China-only data.

Deals ImmunoOncology

Early Data On Amgen’s AMG 133 Show Potential Durability, Dosing Advantage In Obesity

The drug is dosed once every four weeks – compared with Mounjaro and Wegovy’s weekly dosing – but the company also signaled it is considering extended dosing intervals.

Clinical Trials Metabolic Disorders

Y-mAbs Shifts Focus To Approved Drug, Pipeline After Omburtamab CRL

The FDA’s thumbs-down was largely expected after a negative advisory committee review and the path forward for the drug remains unclear – but the company is prioritizing other programs.

Complete Response Letters ImmunoOncology

Ferring Makes Important Milestone For Microbiome With Rebyota Approval

The microbiome therapy won approval for preventing recurrence of Clostridioides difficile infections, but an analyst said the future could be in more targeted approaches.

Approvals Infectious Diseases

Nimbus Nips At BMS’s Heels With Psoriasis Results For TYK2 Inhibitor

Without disclosing data, Nimbus announced positive Phase IIb results for NDI-034858 in psoriasis. The company plans to initiate a Phase III trial next year.

Clinical Trials Business Strategies
See All
UsernamePublicRestriction

Register